Celldex Therapeutics released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. The stock has climbed strongly over the past year, with a year-to-date share price return of 54.42% and a one-year total shareholder return of 101.89%, while the recent 90-day gain of 29.21% suggests momentum has been building into the latest earnings update. On Simply Wall St's numbers, Celldex Therapeutics trades on a price-to-book ratio of 4.6x, which is expensive relative to the broader US Biotechs industry average of 2.5x and a peer group average of 4.4x, signaling a premium valuation. However, using the SWS DCF model, Celldex Therapeutics at $41.71 is trading below an estimated future cash flow value of $96.10, which points to a very large implied discount. The company faces key risks including ongoing clinical trial uncertainty and a current net loss of $300.549 million.
Celldex Therapeutics IncDCF valuation suggests 130% upside, despite weak Q2 results and net loss.
